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Introduction 13
Homogeneity of cell size is a characteristic feature of healthy tissues. While cells from different tissues vary 14 widely in size, within a given tissue cells are strikingly similar in size (1) . In a separate study (co-submitted), we 15 showed that size uniformity in populations of animal cells results from two separate processes. Firstly, during G1, 16 a size-dependent process delays S-phase entry in small cells, giving them more time to grow before their next 17 division. Additionally, twice during the cell cycle, cellular growth rates are adjusted so that small cells actually 18 grow faster than large cells. The molecular mechanisms underlying these regulatory behaviors have not yet been 19 identified. In yeast, the existence of a cell size checkpoint has long been postulated (2, 3) . However, the molecular 20 mechanisms maintaining that checkpoint also remain elusive. 21
The mammalian p38 MAPK pathway participates in numerous biological processes, including the regulation of 22 cell cycle checkpoints. In response to DNA damage or oxidative stress, p38 is activated and induces a cell cycle 23 arrest (4, 5) . Hyperosmotic conditions that shrink cell volume also strongly activate p38 (6) (7) (8) . Furthermore, 24 3 upregulation of the p38 MAPK pathway can lead to increased cell size (9) (10) (11) (12) (13) . These observations raise the 25 possibility that p38 may function to regulate cell size checkpoints in animal cells. 26
Results 27
To identify the molecular pathways linking cell size and cell cycle progression, we searched specifically for 28 perturbations that could disrupt this link. We screened two compound libraries, known as the Novartis MOA 29 (Mechanism-of-Action) box and Kinome box, which together included over 3,000 compounds. The MOA Box 30 contains a dynamically-managed annotated list of compounds curated to maximize coverage of targets, pathways, 31 and bioactivity space ( Figure 1 -Figure supplement 1 ), to facilitate biological discovery by screening and profiling 32 experiments. The Kinome Box is a library containing a wide range of kinase inhibitors that were selected based 33 on their efficiency and specificity (primary targets IC50<1 M, <25 total targets). Compounds from both libraries 34 are thoroughly annotated for primary targets, off-target effects and corresponding potencies. 35
To initiate the screen, unsynchronized HeLa cells were treated with compounds for 24 hours, after which cells 36 were fixed and both the size and cell cycle stage of each cell was measured. The cells expressed the FUCCI cell 37 cycle reporters mAG-hGem and mKO2-hCdt1 (14) , enabling sensitive detection of G1 progression and exit. 38
Additionally, to assay progression through S phase, fixed cells were stained with DAPI. To measure cell size, 39 cells were also stained with a protein dye that provides an accurate measure of cell mass (15) . Following drug 40 treatment, samples were imaged by fluorescence microscopy, and an automated image-processing pipeline was 41 developed to quantify fluorescence intensity within each cell. With this screening strategy, both cell size and cell 42 cycle stage of each cell was measured. Each drug treatment yielded a multi-dimensional joint distribution of cell 43 size and cell cycle indicators ( Figure 1A ). After subsequent data analysis, the single cell measurements from each 44 treatment can be classified into discrete cell cycle stages (Figure 1 -Figure supplement 2 ). Cell count, average cell 45 size, and cell size variability were also calculated, to evaluate how each compound influences cell proliferation 46 and size regulation. 47
In an unsynchronized population, the proportion of cells in a particular cell cycle stage reflects the duration of that 48 stage relative to the entire cell cycle (15) . Plotting the proportion of cells in early G1 versus the average size of 49 early G1 cells, in each screened condition, consistently revealed a negative correlation between these quantities 50 ( Figure 1 , B and C). Treatments that reduced the size of cells in early G1 typically yielded larger proportions of 51 cells in G1, suggesting that G1 duration depends on a cell's initial size. Live-cell tracking of single cells with 52 time-lapse microscopy confirmed that there is a negative correlation between the nuclear size (a correlate of cell 53 size (manuscript co-submitted)) of a cell at birth and its G1 duration ( Figure 1F ), further supporting the 54 hypothesis that G1 length is regulated in a size-dependent manner to promote uniformity among cells. 55
To investigate the pathways that link cell size to G1 length, we identified compounds that altered the average cell 56 size, fraction of cells in G1, or both (i.e. outliers on the plot in Figure 1B and Figure 1 -Figure supplement 3 ). We 57 sorted these "hits" into two different types. The first, which we call on-axis compounds, perturbed both cell size 58 and the proportion of cells in G1, but maintained the coordination between the two. In other words, on-axis 59 compounds produced reciprocally correlated influences on cell size and the fraction of cells in G1. The second 60 class of hits, off-axis compounds, are compounds that disproportionally affected either size or cell cycle 61 progression, resulting in paired values of cell size and G1 fraction that lie off-axis to the trend defined by the 62 majority of screened conditions in Figure 1B . These off-axis compounds may reveal a disruption of the 63 coordination of size and G1 length. 64
To identify the pathways that are associated with either the off-axis or on-axis phenotypes, we used the compound 65 annotations to perform target-enrichment analysis with Fisher's exact test. Specifically, we asked for proteins 66 that are significantly overrepresented in the combined list of targets of either the on-axis or off-axis compounds. 67
This analysis avoids the risk of formulating a hypothesis based on a single drug. Interestingly, we found that the 68 proteins most frequently targeted by the on-axis compounds are PI3K, Akt and mTOR ( Figure 1D ). This suggests 69 that while the PI3K/Akt/mTOR pathways regulate cell size, these pathways are not involved in the coordination 70 of cell growth and cell cycle progression. 71
By contrast, the MAP Kinases were highly enriched among the targets of off-axis compounds ( Figure 1E ). 72
Notably, multiple components of the p38 MAPK pathway, including p38 (MAPK14), MK2 (MAPKAPK2, a 73 direct substrate of p38) and TAK1 (MAP3K7, an essential upstream activator of p38) are ranked in the top 1% of 74 significant targets (p-value<0.01). Over 35 compounds that target the p38 pathway components highlighted in 75 Figure 1E , consistently displayed an off-axis phenotype, suggesting the involvement of the p38 MAPK pathway 76 in the coordination of G1 length with cell size. As an additional test for pathways that control cell size, we ranked 77 compounds based on their effect on cell size variability. Using a similar target-enrichment approach, we generated 78 a list of candidate proteins whose inhibition is associated with increased variability in size. MK2, a downstream 79 substrate of p38 was the highest-ranking target in this list (Figure 1 -Figure supplement 4 ). 80
To test whether the p38 MAPK pathway coordinates G1 length with cell size, we developed a robust assay to 81 quantify this coordination in non-cancerous RPE1 cells. The mTOR inhibitor, rapamycin, is an on-axis compound 82 that perturbs cell size but maintains the coordination of size with G1 length. In a different study (co-submitted), 83 we showed that rapamycin produces a 60% decrease in the average rate of cell growth which is partially 84 counteracted by an 80% increase in cell cycle length to limit the drug's effect on cell size. As shown in Figure 2A , 85 higher concentrations of rapamycin correspond to smaller G1 cells and longer G1 duration, producing a robust 86 negative correlation. To test if p38 is required for the negative correlation of cell size with G1 length, we 87 examined a panel of specific inhibitors against MAPK pathways and tested whether any of these inhibitors break 88 the negative correlation induced by rapamycin. Significantly, inhibition of p38, but not the JNK or ERK 89 pathways, consistently breaks the negative correlation between size and proportion of cells in G1 (Figure 2 B-E, 90 isoforms with regard to size control (13, 16) . One difference between the chemical inhibition and the knockdown 96 experiments is a greater reduction in cell size observed following chemical inhibition of p38. A possible 97 explanation for this difference is the lower specificity of chemical inhibitors as compared to genetic perturbations. 98
Functional redundancy between different p38 isoforms, for example, can partially compensate for the siRNA but 99 not for the pharmacological perturbations. Alternatively, it may be that transfection with siRNA activates 100 nonspecific cellular responses, such as upregulation of innate immune pathways, that lead to an increase in size 101 6 (17) (18) (19) . Nonetheless, these results collectively demonstrate that both chemical and genetic inhibition of p38 102 activity result in loss of coordination between cell size and G1 length. 103
To further test the relationship of p38 to size control, we perturbed MKK3/6/4 by siRNA, which are upstream 104 activators of the p38 pathway. As a control, we also knocked down MKK7, an upstream regulator of JNK. The p38 MAPK pathway participates in cell cycle checkpoints by phosphorylating cell cycle regulators including 109 p27, cyclin D, Rb and CDC25 (4, (20) (21) (22) . To test the mechanisms of the p38-mediated cell size checkpoint, we 110 treated cells with rapamycin, an on-axis drug, to induce a size-dependent lengthening of G1. As expected, 111 rapamycin treatment was accompanied by downregulation of positive G1/S regulators (e.g., Cyclin D, p-Rb, 112
Cdc25A) and upregulation of negative regulators of G1 progression (e.g., p27 Kip1 ) ( Figure 2C ). In contrast, 113 inhibition of p38 disrupted the effect of rapamycin on these four cell cycle regulators ( Figure 2C ), resulting in the 114 loss of compensatory G1 lengthening in small cells. These results suggest that the p38 pathway functions 115 downstream of a cell size sensor to prolong G1 length in small-sized cells and promote cell size uniformity. 116
The hypothesis that p38 regulates cell-size-dependent cell cycle progression predicts that the p38 MAPK pathway 117 is selectively activated in small cells. Figure 2C shows that p38 is, indeed, activated when cell size is decreased 118 by inhibition of mTOR. While this result is consistent with size-dependent p38 activation, it could also have 119 alternative explanations. p38 may be directly activated by the inhibition of mTOR, rather than the indirect 120 influence of mTOR inhibition on cell size. To rule this out, we exploited the separate timing of cell growth and 121 mTOR signaling. Treating cells with the mTOR inhibitor Torin-2, which inhibits cell growth, reduces cell size by 122 over 15% ( Figure 4A ). However, when Torin-2 is washed out, mTOR activity is restored within 1 hour, whereas 123 recovery of cell size proceeds over a period of 14 hours. This "size-recovery experiment" provides an opportunity 124 to observe cells that are smaller than their regular size but are no longer subject to mTOR inhibition ( Figure 4B ). 125
Western-blots of lysates from cells during the recovery phase show that the p38 MAPK remains upregulated after 7 mTOR has resumed normal activity ( Figure 4B ). Further, the timescale of p38 dynamics during the recovery 127 experiments, mirrors the recovery in cell size and not the dynamics of mTOR activity. 128
To further ask whether the p38 MAPK pathway is selectively upregulated in small cells, we employed a p38 129 Kinase Translocation Reporter (KTR) (23) that quantitatively reports p38 activation in live cells. This assay 130 involves a fluorescent reporter that, once phosphorylated by p38 MAPK, shuttles from the nucleus to the 131 cytoplasm. The ratio of cytoplasmic to nuclear (C/N) fluorescence represents a quantitative measure of p38 132 activation. As expected, cells treated with a p38 inhibitor display a lower C/N ratio than untreated cells ( Figure  133 4C). Cells expressing the p38 KTR were treated with a range of concentrations of mTOR inhibitors, decreasing 134 cell size to varying extents. The amount of p38 activity was measured in each condition. The results show that 135 p38 activity is upregulated proportionally to the decrease in cell size ( Figure 4C ). When cells are released from 136 mTOR inhibition, the negative correlation between cell size and p38 activity persists for at least 6 hours after 137 release, long after normal mTOR activity has been restored. As an additional control, we expressed a dual color 138 KTR in the cells, reporting the activity of both p38 and JNK. These measurements showed that while p38 activity 139 is negatively correlated with cell size, JNK activity is not ( Figure 4C ). Together, these results indicate that 140 aberrantly small cells upregulate the p38 MAPK pathway. 141
As a final test of a role for p38 in the maintenance of cell size, we asked whether its activity is necessary for 142 recovery from the decrease in size caused by mTOR inhibition. We repeated the "size recovery experiment" 143 shown in Figure 4A , in the presence or absence of several different p38 inhibitors. As additional controls, we also 144 used inhibitors against two other MAPKs, ERK and JNK. Consistent with our expectation, inhibition of p38, but 145 not of JNK or ERK, repressed the recovery in cell size ( Figure 4D . This delay may hint that the cell growth cycle depends on a commitment point that is 152 cell-cycle-stage-dependent, analogous to the restriction point that regulates the cell division cycle (24) . 153
In this study, we have shown that the p38 MAPK pathway is involved in coordinating cell cycle progression with 154 cell size. Aberrantly small cells display higher p38 MAPK activity and longer duration of growth in the G1 phase 155 of cell cycle. Inhibition of p38 MAPK leads to loss of the compensatory G1 length extension in small cells, 156 resulting in faster proliferation, smaller cell size and increased heterogeneity in size. These results suggest a 157 model whereby the p38 MAPK pathway functions downstream of a cell size sensing process and feeds 158 information about cell size to regulators of cell cycle. Mechanisms by which the p38 MAPK pathway regulates 159 cell cycle progression have been well-established in literature (4, (20) (21) (22) . Here, we have shown that such p38-160 dependent cell cycle control is regulated by cell size. Previously, p38 MAPK has been shown be activated in 161 response to osmotic shock that alters cell volume (6) (7) (8) . The results reported here show that the p38 pathway is 162 activated in cells with reduced cell mass, revealing that a common pathway responds to changes in both cell 163 volume and mass. This finding is not trivial, since, unlike cell mass, cell volume is a labile phenotype that 164 changes over rapid time scales (minutes) and is modulated by ion channels and transporters. In contrast, cell mass 165 changes more slowly (over hours) and is modulated by protein translation and central carbon metabolism. 166
In addition to identifying the roles of p38 in communicating information on size, our study introduced a new 167 strategy to assay chemical screens, particularly of quantitative physiological processes. Screens typically are 168 designed to identify compounds that inhibit a given process leading to a phenotype. In this study we designed a 169 strategy to identify compounds that perturb the relationship between two separate processes: growth and cell 170 proliferation. We hope that strategies such as this may find further utility in drug discovery and other branches of 171 cell physiology. 172 targets. Target enrichment analysis, described below, was carried out using all possible targets (assigned and 38 inferred from data). The target class coverage by percent of the MOA Box is as follows (Figure 1 -Figure  39  supplement 1 To examine the process of recovery in cell size, cells were treated with Torin2 (50 and 25 nM) for 24 hours, 61
washed with PBS and re-incubated with fresh media for the times indicated. Cells were resuspended using trypsin 62
and cell size and cell density was measured using the Multisizer 4 Coulter Counter (Beckman-Coulter, 63
Mississauga, ON) or collected for whole cell lysis at time points indicated in the figures. 64
In the experiment using p38 or JNK KTRs, cells were seeded in 96 well plates and treated with Rapamycin (30, 3, 65 1, 0.3 nM and DMSO controls) for 24 hours. The cells were either fixed and stained or washed with PBS and 66 replaced with fresh DMEM media for 6 hours before fixation and staining. 67 siRNA transfection: RPE1-Geminin cells were seeded in 6-well plates at a density of 2 × 10 5 cells/well. Twenty 68 four hours post-seeding, the cells were transfected with SMARTpool siRNA (25 nM) using DharmaFECT 1 69 transfection reagent according to the manufacturer's instructions. Twenty hours post transfection, the cells were 70
re-suspended using 0.05% trypsin-EDTA (Wisent) and re-seeded into 96-well µclear microplates (Greiner Bio-71 one, Monroe, NC) at a density of 5,000 cells/well. Six hours after re-seeding, cells were treated with Rapamycin 72 (30, 3, 1 and 0.3 nM) or DMSO control for 24 hours before fixation and staining. 73
Fixation, staining and imaging: Cells were fixed in 4% paraformaldehyde (Electron Microscopy Sciences, 74
Hatfield, PA) for 10 minutes, followed by permeabilization in cold methanol at -20°C for 5 minutes. Cells were 75 stained for cell size with 0.4 g/mL Alexa Fluor 647 conjugated succinimidyl ester (SE) for 2 hours to 76 nonspecifically label total protein content. The cells were then labeled for DNA with 1 g/mL DAPI for 10 min. 77
The cells were either imaged using an IN Cell Analyzer Image processing and cell segmentation: Automated image-processing pipelines have been developed using 91
Matlab. The general scheme includes 3 steps: correction for background fluorescence and/or uneven illumination, 92 cell segmentation, and feature quantification. Each step has been optimized according to microscopes, 93 experimental design (e.g., fixed or live cell) and the features needed. The same image processing pipeline and 94 parameters were applied identically to all images from the same experiment. 95 3 To correct for background fluorescence, a background image was constructed and applied per channel. There are 96 two scenarios to construct a background image: either by averaging images containing few or no cells (in the 97 compound screen); or by averaging the background region across all images collected (experiments with KTR 98 cells, and in the time-lapse imaging). Uneven illumination was corrected for images from the compound screen in 99 which the problem is obvious. A flat-field image has been constructed and applied for all channels. The flat-field 100 image was constructed based on the fact that 2N peak in DNA distribution is invariant to cell positions in the 101 image. 102
In the step of cell segmentation, nucleuses were first spotted through a nuclear channel (DNA or H2B), and 103 segmented by seed-based watershed. When cell channel exists, the segmented nucleuses were further used as 104 seeds to segment cells (SE channel) by watershed. The nuclear and cell border were detected with thresholds in 105 corresponding channels, which were either automatically detected or manually selected based on need. 106 collected. The minimum volume ellipsoid (MVE) estimator (2, 3) was applied to pick a smallest volume ellipsoid 117 that consists of around 50% of the total sample. The MVE estimator was a reliable tool to identify robust trend 118 and detect outliers in multivariate data. The subsample of minimum volume ellipsoid was used to calculate the 119 robust covariance matrix (rCov), from which correlation coefficient between S and P was calculated per plate. 120
Further, we calculated the Mahalanobis distance from each data point (a well) to the center of the ellipsoid, and 121 performed thresholding (5% significance) to the Mahalanobis distance to detect the outlier wells. Intuitively, the 122 outlier wells display drastic distinctive phenotype in early G1 cell size and/or its G1-length compared with the 123 control wells (and most drug treatments). Based on rCov, the principle vector of [S, P] was calculated and the 124 angle of each outlier well with reference to the major principle vector was computed. The outlier angles were used 125 to classify on/off-axis outliers: outliers with an angle smaller than 45 degree were classified as on-axis outliers, 126
and otherwise off-axis outliers. The on/off-axis outliers were further filtered separately to lower false-positive rate. 127
In the compound screen, each compound has been tested for at least 6 times (3 concentrations with duplicates); 128 and compounds that have only been identified as outlier once among all treatments were excluded from further 129 analysis. Next with the robust outliers, we performed the target enrichment analysis using hypergeometric test 130 (Fisher's exact test) for each known target of the outliers to identify the target proteins that are significantly 131 highly represented in the outlier compounds. 132
To identify compound treatments that increase cell size variability, median absolute deviation (MAD), a robust 133 measure of variability, of cell size was calculated per well. We observed that cell size MAD is linearly correlated 134 with median cell size (r = 0.964). Accordingly, we normalize the MAD by median cell size to obtain a robust 135 measure of cell-to-cell variability within cell populations. For each well, its normalized MAD is compared to that 136 of the control wells in the same plate to calculate a MAD score. To select for compound treatments with perturbed 137 size variability, a threshold in MAD score was calculated based on the distribution of MAD scores of all control 138 wells (1% significance). The outliers with higher MAD scores compared with the threshold were filtered for 139 repeatability and enriched for target proteins the same way as described above. 140
Time-lapse microscopy: RPE1 cells with stable expression of H2B-mTurquoise and Geminin-mVenus were 141
seeded in 96-well clear microplates (Greiner Bio-one, Monroe, NC) and grown in the incubator for at least 6 142 hours prior to imaging. The cells were imaged with the Operetta High-Content Imaging System. During the 143 imaging, the plate was incubated in the live cell chamber (37°C, 5% CO 2 ) and grown in the same medium 144 (DMEM/F12, 10% FBS) as described above. Widefield fluorescent images of H2B-mTurquoise and Geminin-145 mVenus were collected every 15 minutes at 20X magnification for 50 hours. Under this experimental setting, the 146 microscope could support imaging of up to 4 wells every time. This experiment has been repeated three times, 147
producing similar results as shown in Figure 1F . (Figure 1 -Figure supplement 2) . B. Average size of early G1 cells is negatively correlated with the fraction of cells in early G1. The scatterplot displays the result from one example 384-well plate. Each data point represents one particular compound treatment (or DMSO control). Red circles highlight the conditions that significantly affect the size of early G1 cells or the proportion of cells in G1. The arrows designate examples of on-axis and off-axis compounds (also see Figure 1 -Figure  supplement 3 ). C. Distribution of correlation coefficients between size of early G1 cells and the fraction of cells in G1, calculated for all screened plates (as described in Methods), demonstrating that the two variables are significantly negatively correlated (p<10 -16 ). D, E. Ranked p-values from the target enrichment analysis of on-axis and off-axis compounds respectively (Fisher's exact test). Components of the mTOR pathway and p38 MAPK pathway are among the top-ranked hits that are highlighted. F. Live-cell imaging confirms that the duration of early G1 is negatively correlated with cell size at birth (N=53). The results shown here are representative of three replicate experiments. Early G1 Cell Size (a.u.) 10 Figure 1B) were identified by thresholding (5% significance) the Mahalanobis distance. The outliers were then classified into on-axis or off-axis based on the angle of the data points with reference to the major principle vector. Specifically, outliers with an angle smaller than 45 degree were classified as on-axis outliers, and otherwise off-axis outliers. See Material and Methods -Analysis of the compound screen for details. Figure 2C confirms the chemical inhibitors are efficient towards inhibiting corresponding MAPKs pathway. Cells were treated with indicated inhibitors for 24 hours before collecting lysates. Anisomycin was added to select wells 1 hour prior to making lysates, to activate MAPK pathways. All inhibitors were used at the 'high dose' indicated in Figure 2C and Figure 2 -Figure supplement 2 . A. Cells treated with p38 inhibitors display a lower level of p-HSP27 (downstream of p38). The p38 inhibitors induce a higher level of p-p38. This is due to negative feedback in the p-p38 pathway (1), and the fact that p38 inhibitors prevent p-p38 from phosphorylating downstream substrates, but do not block phosphorylation of p38 itself by upstream regulators. B, C. Cells treated with JNK or MEK I/II inhibitor inactivate the corresponding pathway under Anisomycin induction. The influence of the inhibitor is not obvious under control condition probably due to low basal activation of the pathways. 
